Boehringer Ingelheim has started a phase 2 trial of a drug that could offer the first oral drug for geographic atrophy, a major cause of sight loss ...

Nanoscope Therapeutics is on the brink of filing what could be the first mutation-agnostic gene therapy for incurable eye disease retinitis pigmentosa.